Pillsbury Advises Biosensor Venture Allez Health in $60 Million Series A+ Financing Round

The round was led by Osang Healthcare Co., Ltd., a Korean in-vitro diagnostics company, as a strategic investor, with additional participation from existing investors.

Formerly known as Zense-Life Inc., Allez Health is expected to use the new capital to accelerate growth towards pivotal trials, to support regulatory approval filings, and to scale manufacturing operations, as reported by a company press release.

To learn more about the transaction, click here.

The San Diego-based Pillsbury deal team included Corporate partners Mike Hird and Richard Blaylock, associate Alexander Graham and senior legal analyst Rory O’Neill.